The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists

The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (espec...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina G. Bubnova, Albert S. Galyаvich, Marat V. Ezhov, David M. Aronov, Natalia N. Vinogradova, Gagik R. Galstyan, Viktor S Gurevich, Yuri A. Karpov, Natalia A. Koziolova, Elena D. Kosmacheva, Gennady V. Matyushin, Igor V. Sergienko, Alexander E. Philippov, Iurii Sh. Khalimov
Format: Article
Language:English
Published: Concilium Medicum 2025-01-01
Series:КардиоСоматика
Subjects:
Online Access:https://cardiosomatics.ru/2221-7185/article/viewFile/676903/198223
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849425505922580480
author Marina G. Bubnova
Albert S. Galyаvich
Marat V. Ezhov
David M. Aronov
Natalia N. Vinogradova
Gagik R. Galstyan
Viktor S Gurevich
Yuri A. Karpov
Natalia A. Koziolova
Elena D. Kosmacheva
Gennady V. Matyushin
Igor V. Sergienko
Alexander E. Philippov
Iurii Sh. Khalimov
author_facet Marina G. Bubnova
Albert S. Galyаvich
Marat V. Ezhov
David M. Aronov
Natalia N. Vinogradova
Gagik R. Galstyan
Viktor S Gurevich
Yuri A. Karpov
Natalia A. Koziolova
Elena D. Kosmacheva
Gennady V. Matyushin
Igor V. Sergienko
Alexander E. Philippov
Iurii Sh. Khalimov
author_sort Marina G. Bubnova
collection DOAJ
description The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.
format Article
id doaj-art-ffb549912e554ee7af46bb9e2f862284
institution Kabale University
issn 2221-7185
2658-5707
language English
publishDate 2025-01-01
publisher Concilium Medicum
record_format Article
series КардиоСоматика
spelling doaj-art-ffb549912e554ee7af46bb9e2f8622842025-08-20T03:29:44ZengConcilium MedicumКардиоСоматика2221-71852658-57072025-01-0116152010.17816/CS67690376593The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of EndocrinologistsMarina G. Bubnova0https://orcid.org/0000-0003-2250-5942Albert S. Galyаvich1https://orcid.org/0000-0002-4510-6197Marat V. Ezhov2https://orcid.org/0000-0002-1518-6552David M. Aronov3https://orcid.org/0000-0003-0484-9805Natalia N. Vinogradova4Gagik R. Galstyan5https://orcid.org/0000-0001-6581-4521Viktor S Gurevich6https://orcid.org/0000-0002-6815-444XYuri A. Karpov7https://orcid.org/0000-0003-1480-0458Natalia A. Koziolova8https://orcid.org/0000-0001-7003-5186Elena D. Kosmacheva9https://orcid.org/0000-0001-8600-0199Gennady V. Matyushin10https://orcid.org/0000-0002-0150-6092Igor V. Sergienko11https://orcid.org/0000-0003-1534-3965Alexander E. Philippov12https://orcid.org/0000-0002-4413-5068Iurii Sh. Khalimov13https://orcid.org/0000-0002-7755-7275National Medical Research Center for Therapy and Preventive MedicineKazan State Medical UniversityNational Medical Research Center of Cardiology named after Academician E.I. ChazovaNational Medical Research Center for Therapy and Preventive MedicineClinical Hospital No. 1 (Volynskaya)National Medical Research Center for EndocrinologySt. Petersburg State UniversityNational Medical Research Center of Cardiology named after Academician E.I. ChazovaPerm State Medical University named after E.A. WagnerScientific Research Institute — Regional Clinical Hospital No. 1 named after Professor S.V. OchapovskyProfessor Voino-Yasenetsky Krasnoyarsk State Medical UniversityNational Medical Research Center of Cardiology named after Academician E.I. ChazovaSt. Petersburg State UniversityPavlov First St. Petersburg State Medical UniversityThe presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.https://cardiosomatics.ru/2221-7185/article/viewFile/676903/198223atherosclerosiscardiovascular diseasespreventionlipid-lowering therapystatinspitavastatin
spellingShingle Marina G. Bubnova
Albert S. Galyаvich
Marat V. Ezhov
David M. Aronov
Natalia N. Vinogradova
Gagik R. Galstyan
Viktor S Gurevich
Yuri A. Karpov
Natalia A. Koziolova
Elena D. Kosmacheva
Gennady V. Matyushin
Igor V. Sergienko
Alexander E. Philippov
Iurii Sh. Khalimov
The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
КардиоСоматика
atherosclerosis
cardiovascular diseases
prevention
lipid-lowering therapy
statins
pitavastatin
title The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
title_full The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
title_fullStr The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
title_full_unstemmed The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
title_short The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
title_sort place of original pitavastatin in primary and secondary prevention of cardiovascular diseases interdisciplinary expert consensus of the russian society of cardiology the national atherosclerosis society the russian society of cardiosomatic rehabilitation and secondary prevention and the russian association of endocrinologists
topic atherosclerosis
cardiovascular diseases
prevention
lipid-lowering therapy
statins
pitavastatin
url https://cardiosomatics.ru/2221-7185/article/viewFile/676903/198223
work_keys_str_mv AT marinagbubnova theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT albertsgalyavich theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT maratvezhov theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT davidmaronov theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT natalianvinogradova theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT gagikrgalstyan theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT viktorsgurevich theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT yuriakarpov theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT nataliaakoziolova theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT elenadkosmacheva theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT gennadyvmatyushin theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT igorvsergienko theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT alexanderephilippov theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT iuriishkhalimov theplaceoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandthe
AT marinagbubnova placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT albertsgalyavich placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT maratvezhov placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT davidmaronov placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT natalianvinogradova placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT gagikrgalstyan placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT viktorsgurevich placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT yuriakarpov placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT nataliaakoziolova placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT elenadkosmacheva placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT gennadyvmatyushin placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT igorvsergienko placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT alexanderephilippov placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus
AT iuriishkhalimov placeoforiginalpitavastatininprimaryandsecondarypreventionofcardiovasculardiseasesinterdisciplinaryexpertconsensusoftherussiansocietyofcardiologythenationalatherosclerosissocietytherussiansocietyofcardiosomaticrehabilitationandsecondarypreventionandtherus